Although the cardioprotective effect of estrogen is well recognized, t
he mechanism by which this effect occurs is not well understood. One p
ossible mechanism may involve an alteration in the local vascular equi
librium between prostacyclin (PGI(2)) and thromboxane A(2) (TxA(2)), f
avoring PGI(2). To test this hypothesis, we studied the estrogenic eff
ect on urinary PGI(2)/TxB(2) balance, both acutely and long term, in p
ostmenopausal women. Seven subjects received estradiol (E(2)) during o
ne visit and only the vehicle during another visit (control). Both wer
e administered intravenously for 8 h. Serum E(2) levels of similar to
200 pg/ml were attained after E(2) treatment. An additional eight subj
ects were treated subcutaneously with two 25-mg E(2) pellets for 24 we
eks; the serum E(2) levels averaged between 80 and 120 pg/ml. Also, 12
premenopausal women were used for comparison of baseline prostanoid v
alues with those of postmenopausal women. A highly specific and sensit
ive high-performance liquid chromatography/radioimmunoassay (HPLC-RIA)
was used to quantitate PGI(2) and TxA(2) by measuring their stable me
tabolites, 6-keto-prostaglandin F-1 alpha (6-keto-PGF(1 alpha)) and th
romboxane B-2 (TxB(2)), respectively, in urine. The 6-keto-PGF(1 alpha
) and TxB(2) levels in postmenopausal women were 35.6 +/- 6.5 and 20.5
+/- 3.8 ng/g of creatinine compared with 32.2 +/- 5.3 and 16.7 +/- 3.
9 ng/g in premenopausal women, respectively. After E(2) infusion, ther
e was a significant increase (41%) in mean 6-keto-PGF(1 alpha) levels,
a 35% drop in mean TxB(2) levels, and a significantly greater (65%) 6
-keto-PGF(1 alpha)/TxB(2) ratio, compared to the controls. After long-
term E(2) treatment, there was a progressive decrease in mean TxB(2) l
evels and a transient increase in 6-keto-PGF(1 alpha) levels. The resu
lts of our study suggest that the anticipated effects of E(2) treatmen
t on PGI(2) and TxA(2) metabolism in postmenopausal women do occur.